MicroRNAs: Novel players in hepatitis C virus infection

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 6, 2014, Pages 664-675

  Li, Xiaofei ^a   Yang, Wenjun ^b   Ye, Weiwei ^a   Jin, Lingzhen ^a   He, Jinke ^a   Lou, Lianqing ^a  

^a YIWU CENTRAL HOSPITAL   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; MICRORNA; VIRUS RNA;

ANTIVIRAL THERAPY; ENZYME ACTIVITY; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERACTIONS WITH RNA; LIFE CYCLE; LIPID METABOLISM; LIVER CELL CARCINOMA; LIVER FIBROSIS; MIXED INFECTION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; GENETICS; HEPACIVIRUS; PHYSIOLOGY; VIRAL PHENOMENA AND FUNCTIONS; VIROLOGY;

ANIMALS; HEPACIVIRUS; HEPATITIS C; HUMANS; MICRORNAS; VIRUS PHYSIOLOGICAL PROCESSES;

EID: 84919399037     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.04.008     Document Type: Review

References (94)

1. Lavanchy D. The global burden of hepatitis C. Liver Int 2009, 29 Suppl. 1:74-81.
2. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374. American Association for the Study of Liver D.
3. Lauer G.M., Walker B.D. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
4. Poynard T., Yuen M.F., Ratziu V., Lai C.L. Viral hepatitis C. Lancet 2003, 362:2095-2100.
5. Kiser J.J., Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol 2013, 53:427-449.
6. Farci P., Strazzera R., Alter H.J., Farci S., Degioannis D., Coiana A., et al. Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A 2002, 99:3081-3086.
7. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
8. De Francesco R., Migliaccio G. Challenges and successes in developing new therapies for hepatitis C. Nature 2005, 436:953-960.
9. Guo H., Ingolia N.T., Weissman J.S., Bartel D.P. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010, 466:835-840.
10. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
11. Umbach J.L., Cullen B.R. The role of RNAi and microRNAs in animal virus replication and antiviral immunity. Genes Dev 2009, 23:1151-1164.
12. Meredith L.W., Wilson G.K., Fletcher N.F., McKeating J.A. Hepatitis C virus entry: beyond receptors. Rev Med Virol 2012, 22:182-193.
13. Moradpour D., Penin F., Rice C.M. Replication of hepatitis C virus. Nat Rev Microbiol 2007, 5:453-463.
14. Suzuki T., Ishii K., Aizaki H., Wakita T. Hepatitis C viral life cycle. Adv Drug Deliv Rev 2007, 59:1200-1212.
15. Jackson R.J., Kaminski A. Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. RNA 1995, 1:985-1000.
16. Lindenbach B.D., Rice C.M. Unravelling hepatitis C virus replication from genome to function. Nature 2005, 436:933-938.
17. Chu P.W., Westaway E.G. Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication. Virology 1985, 140:68-79.
18. Chang M., Williams O., Mittler J., Quintanilla A., Carithers R.L., Perkins J., et al. Dynamics of hepatitis C virus replication in human liver. Am J Pathol 2003, 163:433-444.
19. Quinkert D., Bartenschlager R., Lohmann V. Quantitative analysis of the hepatitis C virus replication complex. J Virol 2005, 79:13594-13605.
20. Suzuki T. Assembly of hepatitis C virus particles. Microbiol Immunol 2011, 55:12-18.
21. Jones D.M., McLauchlan J. Hepatitis C virus: assembly and release of virus particles. J Biol Chem 2010, 285:22733-22739.
22. Jopling C.L., Yi M., Lancaster A.M., Lemon S.M., Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005, 309:1577-1581.
23. Randall G., Panis M., Cooper J.D., Tellinghuisen T.L., Sukhodolets K.E., Pfeffer S., et al. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A 2007, 104:12884-12889.
24. Jopling C.L., Schutz S., Sarnow P. Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome. Cell Host Microbe 2008, 4:77-85.
25. Mortimer S.A., Doudna J.A. Unconventional miR-122 binding stabilizes the HCV genome by forming a trimolecular RNA structure. Nucleic Acids Res 2013, 41:4230-4240.
26. Zhang C., Huys A., Thibault P.A., Wilson J.A. Requirements for human Dicer and TRBP in microRNA-122 regulation of HCV translation and RNA abundance. Virology 2012, 433:479-488.
27. Henke J.I., Goergen D., Zheng J., Song Y., Schuttler C.G., Fehr C., et al. microRNA-122 stimulates translation of hepatitis C virus RNA. EMBO J 2008, 27:3300-3310.
28. Shimakami T., Yamane D., Jangra R.K., Kempf B.J., Spaniel C., Barton D.J., et al. Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex. Proc Natl Acad Sci U S A 2012, 109:941-946.
29. Li Y., Masaki T., Yamane D., McGivern D.R., Lemon S.M. Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication. Proc Natl Acad Sci U S A 2013, 110:1881-1886.
30. Machlin E.S., Sarnow P., Sagan S.M. Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc Natl Acad Sci U S A 2011, 108:3193-3198.
31. Bigger C.B., Guerra B., Brasky K.M., Hubbard G., Beard M.R., Luxon B.A., et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004, 78:13779-13792.
32. Schlee M., Roth A., Hornung V., Hagmann C.A., Wimmenauer V., Barchet W., et al. Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009, 31:25-34.
33. Lagos-Quintana M., Rauhut R., Yalcin A., Meyer J., Lendeckel W., Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002, 12:735-739.
34. Murakami Y., Aly H.H., Tajima A., Inoue I., Shimotohno K. Regulation of the hepatitis C virus genome replication by miR-199a. J Hepatol 2009, 50:453-460.
35. Cheng J.C., Yeh Y.J., Tseng C.P., Hsu S.D., Chang Y.L., Sakamoto N., et al. Let-7b is a novel regulator of hepatitis C virus replication. Cell Mol Life Sci 2012, 69:2621-2633.
36. Pedersen I.M., Cheng G., Wieland S., Volinia S., Croce C.M., Chisari F.V., et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 2007, 449:919-922.
37. Meylan E., Tschopp J., Karin M. Intracellular pattern recognition receptors in the host response. Nature 2006, 442:39-44.
38. Pfeffer L.M., Madey M.A., Riely C.A., Fleckenstein J.F. The induction of type I interferon production in hepatitis C-infected patients. J Interferon Cytokine Res 2009, 29:299-306.
39. Pfeffer L.M., Dinarello C.A., Herberman R.B., Williams B.R., Borden E.C., Bordens R., et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 1998, 58:2489-2499.
40. Chen Y., Chen J., Wang H., Shi J., Wu K., Liu S., et al. HCV-induced miR-21 contributes to evasion of host immune system by targeting MyD88 and IRAK1. PLoS Pathog 2013, 9:e1003248.
41. Bhanja Chowdhury J., Shrivastava S., Steele R., Di Bisceglie A.M., Ray R., Ray R.B. Hepatitis C virus infection modulates expression of interferon stimulatory gene IFITM1 by upregulating miR-130A. J Virol 2012, 86:10221-10225.
42. Zhang X., Daucher M., Armistead D., Russell R., Kottilil S. MicroRNA expression profiling in HCV-infected human hepatoma cells identifies potential anti-viral targets induced by interferon-alpha. PLoS ONE 2013, 8:e55733.
43. Friedman R.L., Manly S.P., McMahon M., Kerr I.M., Stark G.R. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 1984, 38:745-755.
44. Wilkins C., Woodward J., Lau D.T., Barnes A., Joyce M., McFarlane N., et al. IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. Hepatology 2013, 57:461-469.
45. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998, 16:225-260.
46. Shwetha S., Gouthamchandra K., Chandra M., Ravishankar B., Khaja M.N., Das S. Circulating miRNA profile in HCV infected serum: novel insight into pathogenesis. Sci Rep 2013, 3:1555.
47. Marquez R.T., Wendlandt E., Galle C.S., Keck K., McCaffrey A.P. MicroRNA-21 is upregulated during the proliferative phase of liver regeneration, targets Pellino-1, and inhibits NF-kappaB signaling. Am J Physiol Gastrointest Liver Physiol 2010, 298:G535-G541.
48. Sun J., Hoshino H., Takaku K., Nakajima O., Muto A., Suzuki H., et al. Hemoprotein Bach1 regulates enhancer availability of heme oxygenase-1 gene. EMBO J 2002, 21:5216-5224.
49. Abdalla M.Y., Britigan B.E., Wen F., Icardi M., McCormick M.L., LaBrecque D.R., et al. Down-regulation of heme oxygenase-1 by hepatitis C virus infection in vivo and by the in vitro expression of hepatitis C core protein. J Infect Dis 2004, 190:1109-1118.
50. Zhu Z., Wilson A.T., Mathahs M.M., Wen F., Brown K.E., Luxon B.A., et al. Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 2008, 48:1430-1439.
51. Hou W., Tian Q., Zheng J., Bonkovsky H.L. MicroRNA-196 represses Bach1 protein and hepatitis C virus gene expression in human hepatoma cells expressing hepatitis C viral proteins. Hepatology 2010, 51:1494-1504.
52. Santhakumar D., Forster T., Laqtom N.N., Fragkoudis R., Dickinson P., Abreu-Goodger C., et al. Combined agonist-antagonist genome-wide functional screening identifies broadly active antiviral microRNAs. Proc Natl Acad Sci U S A 2010, 107:13830-13835.
53. Agnello V., Abel G., Elfahal M., Knight G.B., Zhang Q.X. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999, 96:12766-12771.
54. Miyanari Y., Atsuzawa K., Usuda N., Watashi K., Hishiki T., Zayas M., et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 2007, 9:1089-1097.
55. Huang H., Sun F., Owen D.M., Li W., Chen Y., Gale M., et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A 2007, 104:5848-5853.
56. Shirasaki T., Honda M., Shimakami T., Horii R., Yamashita T., Sakai Y., et al. MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol 2013, 87:5270-5286.
57. Kottilil S., Yan M.Y., Reitano K.N., Zhang X., Lempicki R., Roby G., et al. Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells. Hepatology 2009, 50:34-45.
58. Brunt E.M. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001, 21:3-16.
59. Barba G., Harper F., Harada T., Kohara M., Goulinet S., Matsuura Y., et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 1997, 94:1200-1205.
60. Moradpour D., Englert C., Wakita T., Wands J.R. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 1996, 222:51-63.
61. Hosaka T., Suzuki F., Kobayashi M., Seko Y., Kawamura Y., Sezaki H., et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 2013, 58:98-107.
62. Johansen J.S., Christoffersen P., Moller S., Price P.A., Henriksen J.H., Garbarsch C., et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000, 32:911-920.
63. Schiavon L.L., Narciso-Schiavon J.L., Carvalho Filho R.J., Sampaio J.P., Medina-Pestana J.O., Lanzoni V.P., et al. Serum levels of YKL-40 and hyaluronic acid as noninvasive markers of liver fibrosis in haemodialysis patients with chronic hepatitis C virus infection. J Viral Hepat 2008, 15:666-674.
64. Kamal S.M., Turner B., He Q., Rasenack J., Bianchi L., Al Tawil A., et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis. Hepatology 2006, 43:771-779.
65. Sarma N.J., Tiriveedhi V., Crippin J.S., Chapman W.C., Mohanakumar T., Hepatitis C. Virus-Induced Changes in MicroRNA 107 (miRNA-107) and miRNA-449a Modulate CCL2 by Targeting the Interleukin-6 Receptor Complex in Hepatitis. J Virol 2014, 88:3733-3743.
66. Biswas P., Delfanti F., Bernasconi S., Mengozzi M., Cota M., Polentarutti N., et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 1998, 91:258-265.
67. Seki E., de Minicis S., Inokuchi S., Taura K., Miyai K., van Rooijen N., et al. CCR2 promotes hepatic fibrosis in mice. Hepatology 2009, 50:185-197.
68. Ramachandran S., Ilias Basha H., Sarma N.J., Lin Y., Crippin J.S., Chapman W.C., et al. Virus induced miR200c down modulates FAP-1, a negative regulator of Src signaling and promotes hepatic fibrosis. PLoS ONE 2013, 8:e70744.
69. Zhang X., Arnott J.A., Rehman S., Delong W.G., Sanjay A., Safadi F.F., et al. Src is a major signaling component for CTGF induction by TGF-beta1 in osteoblasts. J Cell Physiol 2010, 224:691-701.
70. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007, 302:1-12.
71. Bushati N., Cohen S.M. microRNA functions. Annu Rev Cell Dev Biol 2007, 23:175-205.
72. Huang S., He X. The role of microRNAs in liver cancer progression. Br J Cancer 2011, 104:235-240.
73. Zhang Y., Wei W., Cheng N., Wang K., Li B., Jiang X., et al. Hepatitis C virus-induced up-regulation of microRNA-155 promotes hepatocarcinogenesis by activating Wnt signaling. Hepatology 2012, 56:1631-1640.
74. Banaudha K., Kaliszewski M., Korolnek T., Florea L., Yeung M.L., Jeang K.T., et al. MicroRNA silencing of tumor suppressor DLC-1 promotes efficient hepatitis C virus replication in primary human hepatocytes. Hepatology 2011, 53:53-61.
75. Huang S., Xie Y., Yang P., Chen P., Zhang L. HCV core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating Wnt1 in HepG2 cells. PLoS ONE 2014, 9:e81730.
76. Fukutomi T., Zhou Y., Kawai S., Eguchi H., Wands J.R., Li J., et al. virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology 2005, 41:1096-1105.
77. Nakano H., Miyazawa T., Kinoshita K., Yamada Y., Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer 2010, 127:1072-1080.
78. Takehara T., Liu X., Fujimoto J., Friedman S.L., Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 2001, 34:55-61.
79. Ishida H., Tatsumi T., Hosui A., Nawa T., Kodama T., Shimizu S., et al. Alterations in microRNA expression profile in HCV-infected hepatoma cells: involvement of miR-491 in regulation of HCV replication via the PI3 kinase/Akt pathway. Biochem Biophys Res Commun 2011, 412:92-97.
80. Douek D.C., Roederer M., Koup R.A. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009, 60:471-484.
81. Sulkowski M.S., Moore R.D., Mehta S.H., Chaisson R.E., Thomas D.L. Hepatitis C and progression of HIV disease. JAMA 2002, 288:199-206.
82. Gupta P., Liu B., Wu J.Q., Soriano V., Vispo E., Carroll A.P., et al. Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection. Virology 2014, 450-451:336-349.
83. Manfe V., Biskup E., Rosbjerg A., Kamstrup M., Skov A.G., Lerche C.M., et al. miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma. PLoS ONE 2012, 7:e29541.
84. Triboulet R., Mari B., Lin Y.L., Chable-Bessia C., Bennasser Y., Lebrigand K., et al. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. Science 2007, 315:1579-1582.
85. Bruni R., Marcantonio C., Tritarelli E., Tataseo P., Stellacci E., Costantino A., et al. An integrated approach identifies IFN-regulated microRNAs and targeted mRNAs modulated by different HCV replicon clones. BMC Genomics 2011, 12:485.
86. Robek M.D., Boyd B.S., Chisari F.V. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005, 79:3851-3854.
87. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
88. McFarland A.P., Horner S.M., Jarret A., Joslyn R.C., Bindewald E., Shapiro B.A., et al. The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. Nat Immunol 2014, 15:72-79.
89. Sarasin-Filipowicz M., Krol J., Markiewicz I., Heim M.H., Filipowicz W. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med 2009, 15:31-33.
90. Murakami Y., Tanaka M., Toyoda H., Hayashi K., Kuroda M., Tajima A., et al. Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. BMC Med Genomics 2010, 3:48.
91. Lanford R.E., Hildebrandt-Eriksen E.S., Petri A., Persson R., Lindow M., Munk M.E., et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327:198-201.
92. Janssen H.L., Reesink H.W., Lawitz E.J., Zeuzem S., Rodriguez-Torres M., Patel K., et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013, 368:1685-1694.
93. Hoffmann T.W., Duverlie G., Bengrine A. MicroRNAs and hepatitis C virus: toward the end of miR-122 supremacy. Virol J 2012, 9:109.
94. Tsai W.C., Hsu S.D., Hsu C.S., Lai T.C., Chen S.J., Shen R., et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest 2012, 122:2884-2897.